COHORT STUDY ON THE SAFETY OF BIMEKIZUMAB IN PATIENTS WITH PLAQUE PSORIASIS, PSORIATIC ARTHRITIS, AXIAL SPONDYLOARTHRITIS, OR HIDRADENITIS SUPPURATIVA: A NON-INTERVENTIONAL POST AUTHORIZATION STUDY

Study identification

• EU PAS number:
  EUPAS1000000003
• Study ID:
  1000000003
• Official title and acronym:
  COHORT STUDY ON THE SAFETY OF BIMEKIZUMAB IN PATIENTS WITH PLAQUE PSORIASIS, PSORIATIC ARTHRITIS, AXIAL SPONDYLOARTHRITIS, OR HIDRADENITIS SUPPURATIVA: A NON-INTERVENTIONAL POST AUTHORIZATION STUDY
• DARWIN EU® study:
  No
• Study countries:
  France

  United States
• Study description:
  No information provided.
• Study status:
  Ongoing

Study timelines

Date when funding contract was signed

Planned:19/12/2022

Actual:19/12/2022

Study start date

Planned:10/03/2025

Actual:13/03/2025

Date of final study report

Planned:31/12/2034

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

UCB Biopharma SRL

Regulatory

• Was the study required by a regulatory body?:
  Yes
• Is the study required by a Risk Management Plan (RMP)?:
  EU RMP category 3 (required)

Other study registration identification numbers and links

PS0038